Welcome to our dedicated page for Biocardia SEC filings (Ticker: BCDA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BioCardia, Inc. SEC filings document a clinical-stage biotechnology and medical-device business focused on cell therapies and related delivery technologies for cardiovascular and pulmonary disease. Recent Form 8-K reports cover Regulation FD disclosures and other events involving CardiAMP clinical data, FDA and PMDA regulatory interactions, the Helix transendocardial delivery catheter, and patent protection for Heart3D Fusion Imaging software.
The company’s filings also record annual operating results, research and development activity, liquidity-related financial disclosures, and Nasdaq continued-listing compliance matters. These documents frame BCDA’s public-company record around product-development programs, regulatory pathways, intellectual property, capital and listing status, risk disclosures, and corporate reporting obligations.
BioCardia, Inc. reported an update on its Nasdaq listing compliance. The company previously fell below the $2.5 million stockholders’ equity requirement under Nasdaq Listing Rule 5550(b)(1) but submitted a plan and received an extension from Nasdaq staff until October 7, 2026 to regain compliance.
Through its at-the-market equity program with H.C. Wainwright & Co., BioCardia sold 4,004,330 shares of common stock between April 1 and June 5, 2026 at an average price of about $1.27 per share, generating net proceeds of $4.9 million. The company believes these transactions have raised stockholders’ equity above $2.5 million as of this report, though Nasdaq will continue to monitor compliance and could delist the stock if a future periodic report does not show the required equity level.
BioCardia, Inc. President and CEO Peter Altman reported an open-market purchase of 5,000 shares of common stock at $0.85 per share. After this transaction, he directly owns 298,266 BioCardia common shares, indicating a modest increase in his personal equity stake in the company.
BioCardia, Inc. reported that it raised approximately $4.4 million through an at-the-market stock sale. The company sold 3,509,604 shares at an average price of $1.279 per share on June 5, 2026, under its at-the-market offering agreement with H.C. Wainwright & Co.
Management anticipates that net proceeds will extend BioCardia’s cash runway into the first quarter of 2027, beyond its planned Japan PMDA submission for CardiAMP Cell Therapy. The company also noted that no warrants were issued in this capital raise, and if currently outstanding warrants from prior financings are fully exercised for cash, the cash runway is expected to extend well beyond PMDA approval and into initial commercial sales.
BioCardia, Inc. announced that FDA Center for Biologics Evaluation and Research meeting minutes confirm the ongoing CardiAMP Heart Failure II Trial may be used to support a Premarket Approval (PMA) application for the CardiAMP Cell Therapy System in ischemic heart failure with reduced ejection fraction.
The company notes that FDA typically prefers two well-designed trials for large indications such as HFrEF, where there are potentially over one million U.S. patients who could benefit from CardiAMP Cell Therapy, so FDA’s acknowledgement of this single ongoing trial as potentially sufficient is an important regulatory step.
CardiAMP Cell Therapy has FDA Breakthrough designation and uses a patient’s own bone marrow cells delivered via a minimally invasive catheter procedure to improve microvascular function in myocardial tissue. Regulatory discussions in Japan suggest three completed heart failure trials may provide enough safety and efficacy evidence for approval there, while U.S. trials have received reimbursement from the Centers for Medicare and Medicaid Services.
BioCardia reported that Japan’s Pharmaceutical and Medical Device Agency (PMDA) issued a Consultation Record that supports submission for regulatory approval of its CardiAMP cell therapy for ischemic heart failure with reduced ejection fraction. The agency confirmed alignment on remaining questions and noted the trial’s positive outcomes were credible.
The company plans to submit in approximately seven months, with the regulatory submission anticipated in Q4 2026. BioCardia estimates that 20,000 of 300,000 ischemic heart failure patients in Japan could initially be eligible if approved. Prior trials showed the minimally invasive procedure was well tolerated, with average exercise tolerance improving 179 seconds and angina episodes reduced by 82%.
BioCardia, Inc. President and CEO Peter Altman reported open-market purchases of the company’s common stock. He bought 200 shares at $0.95 per share on May 19, 2026 and 1,500 shares at $0.92 per share on May 20, 2026. After these transactions, he directly owns 293,266 shares of BioCardia common stock.
BioCardia, Inc. reported preliminary open-label results from its CardiAMP Cell Therapy trial in chronic myocardial ischemia, presented at the EuroPCR conference. The minimally invasive, autologous cell therapy was well tolerated, with no treatment emergent major adverse cardiac events through two years of follow-up.
Patients had already exhausted guideline-directed medical, percutaneous, and surgical options before treatment. After CardiAMP therapy, average exercise tolerance increased by 179 seconds and this benefit persisted over two years. Angina episodes fell by an average of 82% by six months, suggesting meaningful symptom relief for severely symptomatic refractory angina patients.
BioCardia, Inc. President and CEO Peter Altman reported an open-market purchase of 5,700 shares of Common Stock at a weighted average price of $0.92 per share. Following this transaction, he directly holds 291,566 shares. The trade was executed in multiple lots between $0.89 and $1.02 per share.
BioCardia, Inc. President and CEO Peter Altman reported an open-market purchase of common stock. He bought 5,100 shares at a weighted average price of $1.02 per share. Following this transaction, he directly owns 285,866 shares of BioCardia common stock.
BioCardia, Inc. reported first quarter 2026 results, showing a smaller net loss while its balance sheet weakened. Net loss was 2,259 thousand for the three months ended March 31, 2026, compared with 2,712 thousand a year earlier, and net loss per share improved to $0.21 from $0.59. Total costs and expenses fell to 2,266 thousand from 2,726 thousand, reflecting lower research and development and selling, general and administrative spending. Cash and cash equivalents were 951 thousand as of March 31, 2026, down from 2,496 thousand at December 31, 2025, and total assets declined to 1,712 thousand from 3,413 thousand. Stockholders’ equity turned into a deficit of 1,066 thousand at March 31, 2026, compared with positive equity of 895 thousand at year-end 2025, while current liabilities increased to 2,778 thousand. The company highlighted a robust intellectual property portfolio with more than 60 patents and patent applications worldwide, including a newly allowed Japanese patent covering its Heart3D Fusion Imaging software to support CardiAMP Cell Therapy procedures.